- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) — Recruiting • Phase III • NCT06456346.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR. Conditions: Essential Thrombocythemia Interventions: Bomedemstat, Hydroxyurea, Bomedemstat placebo, Hydroxyurea placebo Lead Sponsor: Merck Sharp & Dohme LLC Planned Enrollment: 300 participants